Free Trial
NASDAQ:VINC

Vincerx Pharma (VINC) Stock Price, News & Analysis

Vincerx Pharma logo
$0.05 +0.00 (+4.12%)
As of 05/2/2025 03:50 PM Eastern

About Vincerx Pharma Stock (NASDAQ:VINC)

Key Stats

Today's Range
$0.05
$0.07
50-Day Range
$0.05
$1.26
52-Week Range
$0.05
$18.70
Volume
77,713 shs
Average Volume
423,280 shs
Market Capitalization
$277,925.40
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$40.00
Consensus Rating
Buy

Company Overview

Vincerx Pharma, Inc., a clinical-stage biopharmaceutical company, researches and develops therapies to address unmet medical needs for the treatment of cancer in the United States. It is developing enitociclib, a cyclin-dependent kinase-9 inhibitor that is in Phase 1 clinical trials for treating patients with hematologic malignancies; and VIP236, a small molecule drug conjugate that is in Phase 1 clinical trials to treat solid tumors. The company's preclinical stage product candidates include VIP943 and VIP924 for the treatment of hematologic malignancies. Vincerx Pharma, Inc. was founded in 2019 is based in Palo Alto, California.

Vincerx Pharma Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
51st Percentile Overall Score

VINC MarketRank™: 

Vincerx Pharma scored higher than 51% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Vincerx Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Vincerx Pharma has received no research coverage in the past 90 days.

  • Read more about Vincerx Pharma's stock forecast and price target.
  • Earnings Growth

    Earnings for Vincerx Pharma are expected to grow in the coming year, from ($10.00) to ($6.40) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Vincerx Pharma is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Vincerx Pharma is 0.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Vincerx Pharma has a P/B Ratio of 0.01. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Vincerx Pharma's valuation and earnings.
  • Percentage of Shares Shorted

    2.97% of the float of Vincerx Pharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Vincerx Pharma has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Vincerx Pharma has recently decreased by 2.84%, indicating that investor sentiment is improving.
  • Dividend Yield

    Vincerx Pharma does not currently pay a dividend.

  • Dividend Growth

    Vincerx Pharma does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    2.97% of the float of Vincerx Pharma has been sold short.
  • Short Interest Ratio / Days to Cover

    Vincerx Pharma has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Vincerx Pharma has recently decreased by 2.84%, indicating that investor sentiment is improving.
  • Search Interest

    Only 1 people have searched for VINC on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Vincerx Pharma insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    15.60% of the stock of Vincerx Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    44.02% of the stock of Vincerx Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Vincerx Pharma's insider trading history.
Receive VINC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vincerx Pharma and its competitors with MarketBeat's FREE daily newsletter.

VINC Stock News Headlines

Vincerx Pharma announces plan to delist from Nasdaq
Elon Set to Shock the World by May 1st ?
Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believes will be Elon’s greatest invention ever… Yes, even bigger than Tesla or SpaceX.
Vincerx Pharma announces non-binding LOI for Qumulus AI combination
See More Headlines

VINC Stock Analysis - Frequently Asked Questions

Vincerx Pharma's stock was trading at $5.2560 at the beginning of the year. Since then, VINC stock has decreased by 99.0% and is now trading at $0.0531.
View the best growth stocks for 2025 here
.

Vincerx Pharma, Inc. (NASDAQ:VINC) posted its quarterly earnings results on Thursday, August, 8th. The company reported ($1.00) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($3.40) by $2.40.

Vincerx Pharma's stock reverse split on the morning of Tuesday, January 28th 2025. The 1-20 reverse split was announced on Thursday, January 23rd 2025. The number of shares owned by shareholders was adjusted after the market closes on Monday, January 27th 2025. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Top institutional investors of Vincerx Pharma include Sage Rhino Capital LLC (1.63%). Insiders that own company stock include Ahmed Md Hamdy, Raquel E Izumi, Alexander A Seelenberger and Laura I Bushnell.
View institutional ownership trends
.

Shares of VINC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Vincerx Pharma investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Arista Networks (ANET), Adobe (ADBE), Jabil (JBL) and CymaBay Therapeutics (CBAY).

Company Calendar

Last Earnings
8/08/2024
Today
5/03/2025
Next Earnings (Estimated)
5/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:VINC
Fax
N/A
Employees
60
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$40.00
High Stock Price Target
$40.00
Low Stock Price Target
$40.00
Potential Upside/Downside
+75,229.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-40,160,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$10.50 per share
Price / Book
0.01

Miscellaneous

Free Float
1,891,000
Market Cap
$277,925.40
Optionable
Not Optionable
Beta
1.67
A Beginner's Guide to Investing in Cannabis Cover

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

This page (NASDAQ:VINC) was last updated on 5/3/2025 by MarketBeat.com Staff
From Our Partners